What Pfizer Australia does

Pfizer Australia is a wholly-owned subsidiary of Pfizer Inc. (NYSE: PFE), operating as a biopharmaceutical company across Australia, New Zealand, and Papua New Guinea. Founded circa 1960, the entity has operated locally for over 65 years as part of Pfizer's 175-year global biopharmaceutical heritage. Its core offering is a diversified prescription medicines, vaccines, and therapeutics portfolio spanning six therapeutic areas: Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS), meaning pricing is government-regulated through reimbursement decisions.

The company generates revenue through a multi-channel go-to-market model. Field sales representatives and customer engagement teams engage healthcare professionals directly (supported by the 1800 PFIZER HCP line and 1800 675 229 medical information line). PfizerDirect provides pharmacies with real-time stock visibility and Key Account support via pfizerpharmacyhub.com.au. Hospital sales cover therapeutic areas including anti-infectives. A biopharma wholesaler network handles broader distribution, with primary depot partners trading at minimum $10M annually. Medicines access programs (Cost-Share Agreements, Compassionate Access Programs, Product Familiarisation Programs) supplement standard distribution for eligible patients.

Pfizer Australia's competitive position rests on the Pfizer global brand, the depth of Pfizer Inc.'s R&D pipeline feeding the local portfolio, PBS regulatory listing barriers, and an entrenched commercial ecosystem that includes the PfizerPro HCP portal, dedicated medical information services, clinical trial operations, and policy advocacy (Breakthrough Nation report, Stronger PBS campaign). The company maintains Medicines Australia Code of Conduct transparency reporting and engages in CSR through The Smith Family partnership (since 2016, $550,000+ invested). Leadership is anchored by Managing Director Anne Harris. The subsidiary operates with a lean 51-100 employee headcount consistent with a commercial and corporate team that draws on parent-company R&D and global manufacturing infrastructure.

Name

Pfizer Australia

Legal name

Pfizer Australia Pty Limited

Website

https://pfizer.com.au

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

51–100 employees

Short description

Pfizer Australia is the Sydney-based ANZ/PNG biopharmaceutical subsidiary of Pfizer Inc., selling PBS-listed prescription medicines, vaccines, and therapeutics across six therapeutic areas to healthcare professionals, pharmacies, and hospitals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Prescription medicines
• Biopharmaceutical products
• Vaccines therapeutics
• Clinical trials research
• Hospital pharmaceuticals

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Medicines and Vaccines: Pfizer Australia generates revenue through the sale of prescription medicines, vaccines, and therapeutics distributed via pharmacies, hospitals, and healthcare providers. Products are listed on Australia's Pharmaceutical Benefits Scheme (PBS) which affects pricing and reimbursement.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Pfizer Australia manufactures and sells biopharmaceutical products including prescription medicines, vaccines, and therapeutics across therapeutic areas such as Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. Products are distributed via pharmacies, hospitals, wholesalers, and healthcare providers, with pricing governed by Australia's Pharmaceutical Benefits Scheme (PBS). The company also runs clinical trials, medicines access programs, and healthcare-professional support services.

Product overview

Pfizer Australia operates as a biopharmaceutical company offering a portfolio of medicines, vaccines, and therapeutics across multiple therapeutic areas including Internal Medicine, Inflammation & Immunology, Rare Disease, Oncology, Vaccines, and Hospital. The company provides Consumer Medicine Information and Product Information resources for consumers and healthcare professionals, along with patient support programs, access programs, and health education resources.

Differentiator

Problem solved

Functional benefit

Products and services

• PfizerDirect Pharmacy Service Direct B2B service for pharmacy customers providing real-time stock status and connection with Pfizer's Key Account team via pfizerpharmacyhub.com.au, supporting product ordering, logistics, and supply chain visibility for pharmacies and wholesalers.
• Medicines Access Programs A suite of programs including Cost-Share Agreements, Compassionate Access Programs, and Product Familiarisation Programs designed to facilitate access to Pfizer medicines for eligible patients and support healthcare organisations managing treatment pathways.
• Clinical Trials Clinical trial programs conducted in Australia as part of Pfizer's global medicine development process, supporting research across its therapeutic areas.

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• The Smith FamilycoreOthers · 1 January 2016Since 2016, Pfizer has supported The Smith Family as its Charity of Choice in Australia. Over the course of the partnership, Pfizer has invested more than $550,000 to support education of young Australians in need. Pfizer currently sponsors 72 students on the Learning for Life program, including 35 students who identify as Aboriginal or Torres Strait Islander. Pfizer colleagues volunteer through student profile checking, career activities, and letter/card writing programs.
• McGrath FoundationminorOthersMcGrath Foundation is listed as one of Pfizer's charity impact report partners, indicating a charitable giving or support relationship.
• Medicines AustraliacoreStrategic or Co-development PartnerPfizer Australia is a member of Medicines Australia and committed to transparency reporting under the Medicines Australia Code of Conduct Edition 20. Reports publicly disclose transfers of value to healthcare professionals, sponsorship of third-party educational meetings, grants and donations to healthcare organisations, and support to patient organisations.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bayer Australia: Australian subsidiary of Bayer with portfolio overlap in specialty pharmaceuticals and women's health, plus similar PBS-driven, HCP-focused commercial model. Comparable multinational pharma subsidiary competing in the same Australian market.
• Roche Australia: Australian subsidiary of Roche, another major multinational biopharmaceutical company with a comparable broad therapeutic portfolio including oncology, immunology, and rare disease. Directly comparable as a peer multinational pharma subsidiary operating in the same PBS-regulated market.
• GSK Australia: Australian subsidiary of GSK with strong overlap in vaccines, specialty medicines, and hospital therapeutics. Competes directly with Pfizer across HCP engagement, PBS listings, and respiratory portfolios.
• Novartis Australia: Australian subsidiary of Novartis with overlapping therapeutic areas including oncology, rare disease, and immunology. Operates under the same PBS reimbursement regime and engages HCPs and hospitals through similar field-sales models.
• AstraZeneca Australia: Australian arm of AstraZeneca with overlapping portfolios in oncology, vaccines, and respiratory. Operates the same field-sales, hospital, and PBS-driven commercial model in Australia.
• Johnson & Johnson Innovative Medicine Australia: Pharmaceutical arm of J&J in Australia, with overlapping portfolios in oncology, immunology, and rare disease. Competes for the same HCP relationships, hospital listings, and PBS reimbursement slots as Pfizer Australia.
• Sanofi Australia: Australian subsidiary of Sanofi with portfolio overlap in vaccines, rare disease, and specialty care. Operates the same PBS, HCP, and pharmacy distribution model targeting the same Australian prescriber base.
• Eli Lilly Australia: Australian subsidiary of Eli Lilly with growing focus on oncology, diabetes, and immunology. Operates a similar PBS, HCP, and hospital-focused commercial model targeting the same Australian prescriber base as Pfizer Australia.
• AbbVie Australia: Australian subsidiary of AbbVie with strong overlap in immunology, oncology, and neuroscience. Competes directly with Pfizer for HCP relationships, hospital listings, and PBS positions in Australia.
• MSD Australia (Merck): Australian subsidiary of Merck & Co. with a comparable portfolio in vaccines, oncology, and hospital specialty. Competes head-to-head with Pfizer for HCP attention, hospital listings, and PBS positions.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Australia